Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK109 + AK104 in advanced solid tumors
CTR20212388Phase 2Active
- Sponsor
- Kangrong Dongfang
- Start
- Nov 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pulocimab, cadonilimab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), colorectal cancer (CRC), gastric adenocarcinoma, sponsored by Kangrong Dongfang. Started Nov 2021; status: active.
02
Drugs
pulocimabcadonilimab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)colorectal cancer (CRC)gastric adenocarcinoma
Beyond the preview
Go deeper on CTR20212388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212388.